Opinion|Videos|May 23, 2024
Community Perspectives: First-Line Treatment Considerations for Older Adults with Type 2 Diabetes
Medha Munshi, MD, and James Bailey, III, MD, FACE, ECNU, discuss the current treatment landscape for type 2 diabetes, and highlight key considerations for the selection of first-line treatments for older adults with this condition.
Advertisement
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement
Trending on Patient Care Online
1
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
4
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
5